233 related articles for article (PubMed ID: 25796537)
21. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
Grgic T; Mis L; Hammond JM
Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
[TBL] [Abstract][Full Text] [Related]
22. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Roca S; Quivy A; Gross-Goupil M; Bernhard JC; De Clermont H; Ravaud A
Acta Oncol; 2011 Oct; 50(7):1135-6. PubMed ID: 21726178
[No Abstract] [Full Text] [Related]
24. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
[TBL] [Abstract][Full Text] [Related]
25. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
26. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
27. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.
Daste A; Gross-Goupil M; Roca S; Bernhard JC; Ravaud A
Target Oncol; 2014 Mar; 9(1):81-4. PubMed ID: 23283668
[TBL] [Abstract][Full Text] [Related]
28. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia.
Potter SL; Venkatramani R; Wenderfer S; Graham BH; Vasudevan SA; Sher A; Wu H; Wheeler DA; Yang Y; Eng CM; Gibbs RA; Roy A; Plon SE; Parsons DW
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27748010
[TBL] [Abstract][Full Text] [Related]
29. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
30. mTOR inhibitors in advanced renal cell carcinoma.
Voss MH; Molina AM; Motzer RJ
Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
[TBL] [Abstract][Full Text] [Related]
31. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
Escudier B
J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
[No Abstract] [Full Text] [Related]
32. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
Parikh M; Lara PN
Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
[TBL] [Abstract][Full Text] [Related]
33. [mTOR inhibitors].
Oya M
Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
[TBL] [Abstract][Full Text] [Related]
34. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
Jafri M; Douis H; Porfiri E
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
[No Abstract] [Full Text] [Related]
35. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
36. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
Paterson C; Jones RJ
Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
[No Abstract] [Full Text] [Related]
37. Biallelic
Maroto P; Anguera G; Roldan-Romero JM; Apellániz-Ruiz M; Algaba F; Boonman J; Nellist M; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C
J Natl Compr Canc Netw; 2018 Apr; 16(4):352-358. PubMed ID: 29632054
[TBL] [Abstract][Full Text] [Related]
38. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
39. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
[TBL] [Abstract][Full Text] [Related]
40. The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma.
Hwang C; Heath EI
J Clin Oncol; 2014 Mar; 32(8):729-34. PubMed ID: 24516012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
